GMED moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 65%.
The 10-day RSI Indicator for GMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 20 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMED as a result. In 48 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for GMED turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 26 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The 10-day moving average for GMED crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
GMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 121 of 211 cases where GMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.142). P/E Ratio (17.897) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. GMED’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PHG declined for three days, in 194 of 302 cases, the price declined further within the following month. The odds of a continued downward trend are 64%.
The 10-day RSI Indicator for PHG moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 19 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHG as a result. In 49 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for PHG turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 30 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
PHG broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
PHG moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PHG crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +12.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHG advanced for three days, in 205 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 124 of 201 cases where PHG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.592) is normal, around the industry mean (4.142). P/E Ratio (25.940) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.768) is also within normal values, averaging (11.253). PHG has a moderately high Dividend Yield (0.134) as compared to the industry average of (0.011). P/S Ratio (1.175) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PHG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GMED | PHG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 65 | 69 | |
PRICE GROWTH RATING 1..100 | 73 | 41 | |
P/E GROWTH RATING 1..100 | 83 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PHG's Valuation (9) in the Electronic Production Equipment industry is somewhat better than the same rating for GMED (73) in the Medical Specialties industry. This means that PHG’s stock grew somewhat faster than GMED’s over the last 12 months.
PHG's Profit vs Risk Rating (100) in the Electronic Production Equipment industry is in the same range as GMED (100) in the Medical Specialties industry. This means that PHG’s stock grew similarly to GMED’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is in the same range as PHG (69) in the Electronic Production Equipment industry. This means that GMED’s stock grew similarly to PHG’s over the last 12 months.
PHG's Price Growth Rating (41) in the Electronic Production Equipment industry is in the same range as GMED (73) in the Medical Specialties industry. This means that PHG’s stock grew similarly to GMED’s over the last 12 months.
GMED's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as PHG (96) in the Electronic Production Equipment industry. This means that GMED’s stock grew similarly to PHG’s over the last 12 months.
| GMED | PHG | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 61% |
| Stochastic ODDS (%) | 3 days ago 72% | 3 days ago 67% |
| Momentum ODDS (%) | 3 days ago 53% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 52% | 3 days ago 60% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 60% |
| TrendMonth ODDS (%) | 3 days ago 59% | 3 days ago 56% |
| Advances ODDS (%) | 19 days ago 66% | 19 days ago 66% |
| Declines ODDS (%) | 3 days ago 57% | 3 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 57% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 62% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while PHG’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while PHG’s TA Score has 5 bullish TA indicator(s).
GMED (@Medical/Nursing Services) experienced а -7.28% price change this week, while PHG (@Medical/Nursing Services) price change was -5.70% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -11.44%. For the same industry, the average monthly price growth was -15.18%, and the average quarterly price growth was -18.29%.
GMED is expected to report earnings on Feb 23, 2027.
PHG is expected to report earnings on Feb 01, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with ZBH. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then ZBH could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -2.49% | ||
| ZBH - GMED | 62% Loosely correlated | -0.36% | ||
| SYK - GMED | 62% Loosely correlated | -0.98% | ||
| AORT - GMED | 57% Loosely correlated | -2.00% | ||
| MDT - GMED | 55% Loosely correlated | -0.67% | ||
| STE - GMED | 55% Loosely correlated | +0.39% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CMDT | 28.91 | -0.12 | -0.41% |
| PIMCO Commodity and Bond Strategy Active ETF (CMDT) | |||
| OPP | 6.69 | -0.03 | -0.45% |
| RiverNorth/DoubleLine Strategic Opportunity Fund | |||
| DLMY | 28.81 | -0.73 | -2.49% |
| FT Vest U.S. Equity Dual Directional Buffer ETF - May (DLMY) | |||
| GRW | 28.82 | -0.89 | -2.99% |
| TCW Durable Growth ETF (GRW) | |||
| IWV | 392.77 | -13.90 | -3.42% |
| iShares Russell 3000 ETF (IWV) | |||